Immutep Limited
Immutep Limited
Your view on IMM.AX
Overview
What the company does, where it operates, and who runs it.
About Immutep Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Marc Voigt
- Headquarters
- Australia Square, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Marc Voigt
- Headquarters
- Australia Square, Sydney, NSW, AU
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525.
Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Immutep Limited. Starting points for Immutep Limited: EPS -AUD 0.05, beta 2.22 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Immutep Limited. Immutep Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Immutep Limited. Trailing twelve-month EPS for Immutep Limited stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Analyst ratings
3 ratings- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterJun 2018 | Next quarterJun 2019 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | −AUD 0.02 | −AUD 0.02 | −AUD 0.01 | −AUD 0.01 |
| Lowest estimate | −AUD 0.02 | −AUD 0.02 | −AUD 0.02 | −AUD 0.01 |
| Highest estimate | −AUD 0.02 | −AUD 0.02 | −AUD 0.01 | −AUD 0.01 |
| Number of analysts | 2 | 3 | 3 | 3 |
| A year ago | — | — | −AUD 0.051 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterJun 2018 | Next quarterJun 2019 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 1.70M | AUD 9.62M | AUD 3.88M | AUD 2.00M |
| Lowest estimate | AUD 1.62M | AUD 7.81M | AUD 3.88M | AUD 2.00M |
| Highest estimate | AUD 1.70M | AUD 11.12M | AUD 3.88M | AUD 2.00M |
| Number of analysts | 2 | 3 | 1 | 1 |
| A year ago | — | — | AUD 14.56M | — |
| Growth vs a year ago | — | — | −73.4% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Immutep Limited. Immutep Limited has reported as a listed company since 1988. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AYA.AXArtrya Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| BOT.AXBotanix Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| CUV.AXClinuvel Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| DXB.AXDimerix Limited | Healthcare | Biotechnology | — | ||
| EBR.AXEBR Systems, Inc. | Healthcare | Medical - Devices | — | ||
| IMR.AXImricor Medical Systems, Inc. | Healthcare | Medical - Specialties | — | ||
| MYX.AXMayne Pharma Group Limited | Healthcare | Medical - Pharmaceuticals | — | ||
| OCC.AXOrthocell Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PCVXVaxcyte, Inc. | Healthcare | NASDAQ | $9.3B | ||
| PDSBPDS Biotechnology Corporation | Healthcare | NASDAQ | $43.8M | ||
| PEPGPepGen Inc. | Healthcare | NASDAQ | $265.3M | ||
| PFNDPathfinder Cell Therapy, Inc. | Healthcare | OTC | $66,716 | ||
| PGENPrecigen, Inc. | Healthcare | NASDAQ | $1.5B | ||
| PHARPharming Group N.V. | Healthcare | NASDAQ | $882.4M | ||
| PHATPhathom Pharmaceuticals, Inc. | Healthcare | NASDAQ | $430.8M | ||
| PHGUFPharming Group N.V. | Healthcare | OTC | $1.1B | ||
| PHIOPhio Pharmaceuticals Corp. | Healthcare | NASDAQ | $8.6M | ||
| PHMMFPharma Mar, S.A. | Healthcare | OTC | $1.5B | ||
| PHRM.CNPharmaTher Holdings Ltd. | Healthcare | CNQ | $9.1M | ||
| PHRRFPharmaTher Holdings Ltd. | Healthcare | OTC | $5.3M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| AVDSAvantis International Small Cap Equity ETF | $379M in assets | — | |
Largest holders first, then the funds most concentrated in IMM.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Immutep Limited. Coverage tracks Immutep Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Immutep Limited.